Continuous manufacturing (CM) has become a contentious topic in the modern pharmaceutical lexicon, driven by divergent ...

Bryan O’Donnell, Head of Quality at Gaelic Laboratories, explains how to navigate GMP challenges to ensure your company ...

According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

Viracta Therapeutics, Inc., a clinical-stage precision oncology company dedicated to treating and preventing virus-associated ...

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

4Q Earnings: $3.7 billion (loss of $1.2 billion 4Q23) FY Earnings: $17.1 billion (earnings were $365 million FY23) ...

Entering 2025, the CDMO industry is at a crossroads. Reflecting on conversations over the past year—with CEOs navigating ...

Pharmapack Europe has announced the winners of its newly reformatted Pharmapack Awards, recognizing excellence in six key ...

PacBio, a developer of high-quality, accurate sequencing solutions, has appointed David Ruggiero as the company’s new Global ...

CDMOs: Challenges & Opportunities in a Big Year of Change. Gil Roth, President of the Pharma & Biopharma Outsourcing Association, shared his insights in the CPHI Annual Report 202 ...

The Chan Zuckerberg Initiative (CZI), in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading ...